MURPHY ANDREW J
SEC CIK 1796226 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | EVP Research | 47.8K | — | $42.34M | 50 | 2021-08-16 | 2025-12-09 |
Most active insiders at REGN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | POON CHRISTINE A | Dir | — | $4.25M |
| 2 | McCourt Marion | EVP Commercial | — | $2.00M |
| 3 | Zoghbi Huda Y | Dir | — | $1.92M |
| 4 | Pitofsky Jason | VP Ctrl | — | $1.87M |
| 5 | Bassler Bonnie L | Dir | — | $1.77M |
| 6 | Guarini Kathryn | Dir | — | $660.0K |
| 7 | RYAN ARTHUR F | Dir | — | $434.7K |
| 8 | MURPHY ANDREW J | EVP Research | — | — |
| 9 | Fenimore Christopher R. | EVP Fin CFO | — | — |
| 10 | Schenkein David P | Dir | — | — |
Transactions 50
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-11 | 2025-12-09 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $701.51 | -4,229 | 47.8K | -8% | -$2.97M | |
| D | 2025-12-09 | 2025-12-05 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +3,715 | 53.8K | +7% | $0 |
| D | 2025-12-09 | 2025-12-08 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $712.94 | -1,699 | 52.1K | -3% | -$1.21M |
| D | 2025-10-31 | 2025-10-29 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $555.67 | +35.0K | 84.1K | +71% | +$19.45M |
| D | 2025-10-31 | 2025-10-29 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $648.82 | -32.5K | 51.6K | -39% | -$21.08M |
| D | 2025-10-31 | 2025-10-30 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | G - Gift | $0.00 | -1,538 | 50.0K | -3% | $0 |
| 2024-12-18 | 2024-12-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $730.81 | -1,054 | 49.1K | -2% | -$770.3K | |
| D | 2024-12-10 | 2024-12-06 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +3,499 | 50.6K | +7% | $0 |
| D | 2024-12-10 | 2024-12-09 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $787.00 | -492 | 50.1K | -1.0% | -$387.2K |
| 2024-11-12 | 2024-11-08 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | G - Gift | $0.00 | -1,185 | 47.1K | -2% | $0 | |
| DM | 2024-08-15 | 2024-08-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $1,153.15 | -6,363 | 48.6K | -12% | -$7.34M |
| D | 2024-08-15 | 2024-08-13 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $399.66 | +20.0K | 68.3K | +41% | +$7.99M |
| D | 2024-08-15 | 2024-08-13 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $1,141.49 | -13.6K | 54.7K | -20% | -$15.57M |
| D | 2024-03-15 | 2024-03-13 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $399.66 | +20.0K | 68.3K | +41% | +$7.99M |
| DM | 2024-03-15 | 2024-03-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $956.47 | -5,783 | 52.9K | -10% | -$5.53M |
| D | 2024-03-15 | 2024-03-13 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $971.82 | -14.2K | 54.1K | -21% | -$13.82M |
| 2023-12-14 | 2023-12-12 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $856.71 | -7,657 | 48.3K | -14% | -$6.56M | |
| DM | 2023-12-12 | 2023-12-08+ | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $844.05 | -6,657 | 58.5K | -10% | -$5.62M |
| D | 2023-12-12 | 2023-12-08 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +3,199 | 61.7K | +5% | $0 |
| DM | 2023-12-06 | 2023-12-05 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $817.44 | -6,536 | 59.4K | -10% | -$5.34M |
| D | 2023-12-06 | 2023-12-04 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $270.43 | +20.0K | 79.4K | +34% | +$5.41M |
| D | 2023-12-06 | 2023-12-04 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $813.58 | -13.5K | 66.0K | -17% | -$10.95M |
| D | 2023-11-15 | 2023-11-13 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $270.43 | +20.0K | 79.4K | +34% | +$5.41M |
| D | 2023-11-15 | 2023-11-13 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $795.69 | -13.5K | 65.9K | -17% | -$10.75M |
| DM | 2023-11-15 | 2023-11-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $799.17 | -6,492 | 59.4K | -10% | -$5.19M |
| 2023-05-10 | 2023-05-09 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | G - Gift | $0.00 | -1,326 | 59.4K | -2% | $0 | |
| D | 2022-12-20 | 2022-12-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +4,129 | 60.7K | +7% | $0 |
| 2022-12-13 | 2022-12-09 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $753.28 | -492 | 56.6K | -0.9% | -$370.6K | |
| DM | 2022-11-16 | 2022-11-15 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $727.81 | -3,720 | 60.4K | -6% | -$2.71M |
| D | 2022-11-16 | 2022-11-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | G - Gift | $0.00 | -1,360 | 57.1K | -2% | $0 |
| D | 2022-11-16 | 2022-11-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $179.13 | +10.0K | 67.1K | +18% | +$1.79M |
| D | 2022-11-16 | 2022-11-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $746.00 | -6,280 | 60.8K | -9% | -$4.68M |
| DM | 2022-08-17 | 2022-08-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $645.49 | -3,513 | 60.0K | -6% | -$2.27M |
| D | 2022-08-17 | 2022-08-15 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $179.13 | +10.0K | 68.5K | +17% | +$1.79M |
| D | 2022-08-17 | 2022-08-15 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $634.25 | -6,487 | 62.0K | -9% | -$4.11M |
| DM | 2022-05-18 | 2022-05-17 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $663.68 | -3,543 | 59.9K | -6% | -$2.35M |
| D | 2022-05-18 | 2022-05-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $179.13 | +10.0K | 68.5K | +17% | +$1.79M |
| D | 2022-05-18 | 2022-05-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $648.31 | -6,457 | 62.0K | -9% | -$4.19M |
| DM | 2022-02-16 | 2022-02-15 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $629.34 | -3,540 | 61.9K | -5% | -$2.23M |
| D | 2022-02-16 | 2022-02-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $179.13 | +10.0K | 68.5K | +17% | +$1.79M |
| D | 2022-02-16 | 2022-02-14 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $626.79 | -6,460 | 62.0K | -9% | -$4.05M |
| 2021-12-14 | 2021-12-11 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $664.34 | -697 | 58.5K | -1% | -$463.0K | |
| DM | 2021-12-10 | 2021-12-10 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $666.27 | -7,122 | 64.1K | -10% | -$4.75M |
| D | 2021-12-10 | 2021-12-09 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $657.11 | -9,378 | 66.3K | -12% | -$6.16M |
| D | 2021-12-10 | 2021-12-09 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $52.03 | +16.5K | 75.7K | +28% | +$858.5K |
| D | 2021-12-10 | 2021-12-08 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +3,462 | 59.2K | +6% | $0 |
| DM | 2021-11-17 | 2021-11-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | S - Sale+OE | $647.17 | -7,167 | 61.5K | -10% | -$4.64M |
| D | 2021-11-17 | 2021-11-15 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | F - Tax | $641.50 | -9,412 | 62.9K | -13% | -$6.04M |
| D | 2021-11-17 | 2021-11-15 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | M - OptEx | $52.03 | +16.6K | 72.3K | +30% | +$862.6K |
| D | 2021-11-17 | 2021-08-16 | REGN | Regeneron Pharmaceuticals | MURPHY ANDREW J | EVP Research | G - Gift | $0.00 | -1,645 | 55.7K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations